Randomised phase II trial of irinotecan plus cisplatin vs irinotecan cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

摘要

Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mg m⁻² on days 1 and 8 and cisplatin 60 mg m⁻² on day 1 with (n=55) or without (n=54) etoposide 50 mg m⁻² on days 1–3 with granulocyte colony-stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further studies.